New protection against Haemophilus influenzae type b infections in infants and young children.
Invasive Haemophilus influenzae type b (Hib) infections carry high morbidity and mortality, primarily due to meningitis among infants less than 1 year of age. Two new vaccines, HbOC and PRP-OMP, have been developed and licensed to prevent invasive Hib infections in infants and young children. New recommendations advise clinicians to begin immunization for Hib at 2 months of age and to complete the designated series. This article details the new Hib immunization schedule for all pediatric clients between 2 months and 5 years. Additionally, public-health measures toward the prevention of serious pediatric morbidity and mortality are covered.
Reece
S M
SM
Family and Community Health Graduate Nurse Practioner Program, University of Massachusetts, Lowell.
D001428:Bacterial Vaccines / Q000009:adverse effects / Q000600:supply & distribution / Q000627:therapeutic use*; D002675:Child, Preschool; D006192:Haemophilus Infections / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D006193:Haemophilus influenzae; D006801:Humans; D007115:Immunization Schedule; D015994:Incidence; D007223:Infant; D012307:Risk Factors
D001428:Bacterial Vaccines